NUVB logo

NUVB
Nuvation Bio Inc - Ordinary Shares - Class A

3,099
Mkt Cap
$1.56B
Volume
2.64M
52W High
$9.75
52W Low
$1.57
PE Ratio
-7.49
NUVB Fundamentals
Price
$4.49
Prev Close
$4.45
Open
$4.45
50D MA
$4.72
Beta
1.55
Avg. Volume
3.3M
EPS (Annual)
-$0.5991
P/B
4.96
Rev/Employee
$211,080.54
$2,743.76
Loading...
Loading...
News
all
press releases
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·4d ago
News Placeholder
More News
News Placeholder
Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth
Nuvation Bio (NUVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·5d ago
News Placeholder
Nuvation Bio (NUVB) Projected to Post Earnings on Monday
Nuvation Bio (NYSE:NUVB) will be releasing its Q1 2026 earnings after the market closes on Monday, May 4. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-4-nuvation-bio-inc-stock...
MarketBeat·5d ago
News Placeholder
Nuvation Bio Announces National Comprehensive Cancer Network Adds Taletrectinib (IBTROZI) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
Nuvation Bio Announces National Comprehensive Cancer Network Adds Taletrectinib (IBTROZI) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers Nuvation...
PR Newswire·5d ago
News Placeholder
Are Options Traders Betting on a Big Move in Nuvation Bio Stock?
Investors need to pay close attention to NUVB stock based on the movements in the options market lately.
Zacks·10d ago
News Placeholder
Nuvation Bio Announces IBTROZI (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026
Nuvation Bio Announces IBTROZI (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026 Nuvation Bio Announces IBTROZI (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at...
PR Newswire·11d ago
News Placeholder
Nuvation Bio (NYSE:NUVB) Insider Kerry Wentworth Sells 36,750 Shares
Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) insider Kerry Wentworth sold 36,750 shares of the business's stock in a transaction dated Friday, April 17th. The shares were sold at an average price...
MarketBeat·11d ago
News Placeholder
Insider Selling: Nuvation Bio (NYSE:NUVB) Insider Sells 50,000 Shares of Stock
Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) insider Dongfang Liu sold 50,000 shares of the business's stock in a transaction dated Friday, April 17th. The stock was sold at an average price of...
MarketBeat·11d ago
News Placeholder
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026 Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May...
PR Newswire·12d ago
News Placeholder
Wedbush Reaffirms Outperform Rating for Nuvation Bio (NYSE:NUVB)
Wedbush reaffirmed an "outperform" rating and set a $11.00 price target on shares of Nuvation Bio in a research note on Thursday...
MarketBeat·16d ago
<
1
2
...
>

Latest NUVB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.